The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation
Abstract
Delivery of nucleic acids with positively charged lipid nanoparticles ((+)NPs) is widely used as research reagents and potentially for therapeutics due to their ability to deliver nucleic acids into the cell cytoplasm. However, in most reports little attention has been made to their toxic effects. In the present study, we performed comprehensive analyses of the potential toxicity associated with (+)NPs. Mice treated with (+)NPs showed increased liver enzyme release and body weight loss compared to mice treated with neutral or negatively charged NPs ((-)NPs), suggesting hepatotoxicity. Intravenous administration of (+)NPs induced interferon type I response and elevated mRNA levels of interferon responsive genes 15-25-fold higher than neutral and (-)NPs in different subsets of leukocytes. Moreover, treatment with (+)NPs provoked a dramatic pro-inflammatory response by inducing Th1 cytokines expression (IL-2, IFN gamma and TNF alpha) 10-75-fold higher than treatment with control particles. Finally, we showed that activation of TLR4 might serve as the underlying mechanism for induction of an immune response when (+)NPs are used. These results suggest that a careful attention must be made when different types of (+)NPs are being developed as nanotherapeutics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cationic and ionizable lipids have also been reported to stimulate the secretion of pro-inflammatory cytokines and reactive oxygen species170–173.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [170]
In the citing paper
“Although the immunogenicity of these lipids has not yet been fully understood, complement system and Toll-like receptors may participate in innate immune activation170,173–175.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [170]
In the citing paper
“In vivo application of lipid nanoparticles has been reported to induce liver and lung injuries in rodents170,173, which may be attributed to the cytotoxicity of the materials and the induction of”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [170]
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
RNA interference is mediated by 21- and 22-nucleotide RNAsPreprint
Elbashir, S. M., Lendeckel, W., & Tuschl, T. (2001) · Genes & Development · doi:10.1101/gad.862301 · Cited by 3,354
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
Interfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H., Maraganore, J. M., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,223
NanoGenotoxicology: The DNA damaging potential of engineered nanomaterials
Singh, N., Manshian, B. B., Jenkins, G. J. S., Griffiths, S. M., Williams, P. M., Maffeïs, T. G. G., Wright, C. J., & Doak, S. H. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.04.009 · Cited by 1,212
LPS, TLR4 and infectious disease diversity
Miller, S., Ernst, R. K., & Bader, M. W. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1068 · Cited by 1,059
Williams, D. F. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.07.027 · Cited by 971
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J., Albuquerque, R., Yamasaki, S., Itaya, M., Pan, Y., et al. (2008) · Nature · doi:10.1038/nature06765 · Cited by 939
Minireview: Nanoparticles and the Immune System
Zolnik, B. S., González-Fernández, A., Sadrieh, N., & Dobrovolskaia, M. A. (2010) · Endocrinology · doi:10.1210/en.2009-1082 · Cited by 914
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent
de Visser, K. E., Korets, L. V., & Coussens, L. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.014 · Cited by 818
Park, H. S., Jung, H. Y., Park, E. Y., Kim, J., Lee, W. J., & Bae, Y. S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3589 · Cited by 635
Balkwill, F. R., & Coussens, L. M. (2004) · Nature · doi:10.1038/431405a · Cited by 626
Kirby, C. J., Clarke, J., & Gregoriadis, G. (1980) · Biochemical Journal · doi:10.1042/bj1860591 · Cited by 592
Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo
Judge, A. D., Bola, G., Lee, A. C. H., & MacLachlan, I. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.002 · Cited by 571
Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target
Peer, D., Park, E. J., Morishita, Y., Carman, C. V., & Shimaoka, M. (2008) · Science · doi:10.1126/science.1149859 · Cited by 491
Self-citationFormation and Intracellular Trafficking of Lipoplexes and Polyplexes
Elouahabi, A., & Ruysschaert, J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.12.006 · Cited by 464
Robbins, M., Judge, A. D., & MacLachlan, I. (2009) · Oligonucleotides · doi:10.1089/oli.2009.0180 · Cited by 463
Bae, Y. S., Lee, J. H., Choi, S. H., Kim, S. A., Almazan, F., Witztum, J. L., & Miller, Y. I. (2008) · Circulation Research · doi:10.1161/circresaha.108.181040 · Cited by 435
Yang, D., Chen, Q., Su, S. B., Zhang, P., Kurosaka, K., Caspi, R. R., Michalek, S. M., Rosenberg, H. F., Zhang, N., & Oppenheim, J. J. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20062027 · Cited by 352
Oxygen Radical-Mediated Pulmonary Toxicity Induced by Some Cationic Liposomes
Dokka, S., Toledo, D., Shi, X., Castranova, V., & Rojanasakul, Y. (2000) · Pharmaceutical Research · doi:10.1023/a:1007504613351 · Cited by 349
Development of Lipidoid–siRNA Formulations for Systemic Delivery to the Liver
Akinc, A., Goldberg, M., Qin, J., Dorkin, J. R., Gamba-Vitalo, C., Maier, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Manoharan, M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.36 · Cited by 323
Overcoming the Innate Immune Response to Small Interfering RNA
Judge, A. D., & MacLachlan, I. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.179 · Cited by 281
IL-17 and Th17 cells in human inflammatory diseases
Miossec, P. (2009) · Microbes and Infection · doi:10.1016/j.micinf.2009.04.003 · Cited by 245
Szajnik, M. E., Szczepański, M. J., Czystowska, M., Elishaev, E., Mandapathil, M., Nowak‐Markwitz, E., Spaczyński, M., & Whiteside, T. L. (2009) · Oncogene · doi:10.1038/onc.2009.289 · Cited by 226
Apétoh, L., Tesnière, A., Ghiringhelli, F., Kroemer, G., & Zitvogel, L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0427 · Cited by 224
Nanomedicine based approaches for the delivery of siRNA in cancer
Özpolat, B., Sood, A. K., & Lopez‐Berestein, G. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02191.x · Cited by 221
Peer, D., & Margalit, R. (2004) · Neoplasia · doi:10.1593/neo.03460 · Cited by 214
Self-citationPark, H., CHUN, J., Jung, H., CHOI, C., & Bae, Y. H. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.09.012 · Cited by 209
RNAi-mediated CCR5 Silencing by LFA-1-targeted Nanoparticles Prevents HIV Infection in BLT Mice
Kim, S. S., Peer, D., Kumar, P., Subramanya, S., Wu, H., Asthana, D., Habiro, K., Yang, Y., Manjunath, N., Shimaoka, M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.271 · Cited by 209
Self-citationSzebeni, J., Alving, C. R., Rosivall, L., Bünger, R., Baranyi, L., Bedöcs, P., Tóth, M., & Barenholz, Y. (2007) · Journal of Liposome Research · doi:10.1080/08982100701375118 · Cited by 199
Ikebe, M., Kitaura, Y., Nakamura, M., Tanaka, H., Yamasaki, A., Nagai, S., 和田, 純., Yanai, K., Koga, K., Sato, N., et al. (2009) · Journal of Surgical Oncology · doi:10.1002/jso.21392 · Cited by 177
Injac, R., Perše, M., Obermajer, N., Torres, V. M., Prijatelj, M., Djordjevic, A. N., Cerar, A., & Štrukelj, B. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.04.048 · Cited by 167
Suppression of immunostimulatory siRNA-driven innate immune activation by 2′-modified RNAs
Sioud, M., Furset, G., & Cekaite, L. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.06.177 · Cited by 151
Understanding How Lipopolysaccharide Impacts CD4 T-Cell Immunity
Vella, A. T., & McAleer, J. P. (2008) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v28.i4.20 · Cited by 146
The immunogenicity of tumor cell death
Kepp, O., Tesnière, A., Zitvogel, L., & Kroemer, G. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32831bc375 · Cited by 124
Soenen, S. J., Illyés, E., Vercauteren, D., Braeckmans, K., Májer, Z., Smedt, S. C. D., & Cuyper, M. D. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.08.050 · Cited by 115
DiC14‐amidine cationic liposomes stimulate myeloid dendritic cells through Toll‐like receptor 4
Tanaka, T., Legat, A., Adam, E., Steuve, J., Gatot, J., Vandenbranden, M., Ulianov, L., Lonez, C., Ruysschaert, J., Muraille, É., et al. (2008) · European Journal of Immunology · doi:10.1002/eji.200737998 · Cited by 98
Ko, Y. T., Falcão, C. B., & Torchilin, V. P. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900006h · Cited by 71
Peng, X., Li, Y., Yang, L., Mao, Y.-Q., Yang, H., Liu, J., Zhang, D., Chen, L.-J., & Wei, Y.-Q. (2008) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-27-46 · Cited by 50
Podesta, J. E., & Kostarelos, K. (2009) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(09)64017-9 · Cited by 45
IL-17 inhibits human Th1 differentiation through IL-12Rβ2 downregulation
Toh, M., Kawashima, M., Zrioual, S., Hot, A., Miossec, P., & Miossec, P. (2009) · Cytokine · doi:10.1016/j.cyto.2009.07.013 · Cited by 43
Tluk, S., Jurk, M., Forsbach, A., Weeratna, R. D., Samulowitz, U., KRIEG, A. M., Bauer, S., & Vollmer, J. (2009) · International Immunology · doi:10.1093/intimm/dxp030 · Cited by 36
Mukherjee, K., Sen, J., & Chaudhuri, A. (2005) · FEBS Letters · doi:10.1016/j.febslet.2004.11.116 · Cited by 30
Diseases that may benefit from manipulating the Th17 pathway
Miossec, P. (2009) · European Journal of Immunology · doi:10.1002/eji.200839088 · Cited by 28
Shi, W., Tang, Q., Chen, X., Cheng, P., Jiang, P., Jing, X.-M., Chen, X., Chen, P., Wang, Y., Wei, Y., et al. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0444-5 · Cited by 28
Systemic siRNA delivery to leukocyte-implicated diseases
Peer, D., & Shimaoka, M. (2009) · Cell Cycle · doi:10.4161/cc.8.6.7936 · Cited by 28
Self-citationLipoxygenase May Be Involved in Cationic Liposome-Induced Macrophage Apoptosis
Takano, S., Aramaki, Y., & Tsuchiya, S. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5731 · Cited by 21
DiC14-amidine confers new anti-inflammatory properties to phospholipids
Lonez, C., Legat, A., Vandenbranden, M., & Ruysschaert, J. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7520-1 · Cited by 16
RNAi Nanoparticles in The Service of Personalized Medicine
Kedmi, R., & Peer, D. (2009) · Nanomedicine · doi:10.2217/nnm.09.74 · Cited by 9
Self-citation
Cited by
Sorted by citations
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Progress and challenges towards targeted delivery of cancer therapeutics
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-03705-y · Cited by 2,220
Self-citationTreating metastatic cancer with nanotechnology
Schroeder, A., Heller, D. A., Winslow, M. M., Dahlman, J. E., Pratt, G. W., Langer, R., Jacks, T., & Anderson, D. G. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3180 · Cited by 1,175
“Recent studies have identified cytokines that are upregulated after the administration of positively charged nanoparticle”
BackgroundConcepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine
Donahue, N. D., Acar, H., & Wilhelm, S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.04.008 · Cited by 985
“Mice that were intravenously injected with positively charged lipid nanoparticles experienced severe adverse effects, including hepatotoxicity, weight loss, and a proinflammatory response, compared tomice injectedwith neutral or negatively charged nanoparticles [156].”
BackgroundKnocking down disease: a progress report on siRNA therapeutics
Wittrup, A., & Lieberman, J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3978 · Cited by 827
Metadata
- Authors
- Kedmi, R., Ben-Arie, N., & Peer, D.
- Affiliations
- Tel Aviv University (IL)
- Corresponding author
- Peer, Dan
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 31
- Issue
- 26
- Pages
- 6867-6875
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2126020016
- Cited by
- 546
- References
- 52
- Citations by year
- 2026: 39 · 2025: 60 · 2024: 67 · 2023: 52 · 2022: 54 · 2021: 33 · 2020: 31 · 2019: 29 · 2018: 26 · 2017: 31 · 2016: 14 · 2015: 15 · 2014: 19 · 2013: 27 · 2012: 25
- FWCI
- 9.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Biomaterials (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- nanoparticle toxicity, TLR4, hepatotoxicity, inflammatory cytokines, Th1 response, nucleic acid delivery, nanotherapeutics, immune activation
- MeSH terms
- Animals, Immunity, Inflammation, Lipids, Mice, Inbred C57BL, Particle Size, Surface Properties, RNA, Small Interfering, Toll-Like Receptor 4, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
